

BIOGEN IDEC - “Refuse to File Letter” to Lemtrada = Modest Positive for BIIB

<https://marketpublishers.com/r/BB7CEC22E23EN.html>

Date: August 2012

Pages: 2

Price: US\$ 90.00 (Single User License)

ID: BB7CEC22E23EN

Abstracts

Delay in the launch of Sanofi’s Lemtrada (alemtuzumab, anti-CD52 mAbs, RRMS) by at least 6 months or more will be perceived as a modest positive for Biogen Idec (BIIB) which should continue to dominate the MS space. BIIB has been one of our top picks for 2012 with its promise of growth on the strength of its marketed products and pipeline. It is poised to enrich its revenue stream and MS franchise in 2012/13 with the launch of oral BG-12. Clinical news flow from... for more detail, please read our report released on 27th August, 2012 on BIIB titled, “Refuse to File Letter” to Lemtrada = Modest Positive for BIIB”.

I would like to order

Product name: BIOGEN IDEC - "Refuse to File Letter" to Lemtrada = Modest Positive for BIIB

Product link: <https://marketpublishers.com/r/BB7CEC22E23EN.html>

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BB7CEC22E23EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970